Tag: Maytansinoid-Payload
FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...
ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...
Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
The Phase 3 SOROYA trial demonstrated promising response rates with mirvetuximab soravtansine, previously known as IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...
A New Maytansinoid-Payload for Antibody-drug Conjugates Development
Established in 2004, Creative Biolabs, a highly specialized company in advanced antibody biochemistry and engineering, released a novel, high-quality, maytansinoid-payload for the development of...
